Saturday, May 30, 2026 U.S. Edition · Independent
Markets
CMPS 13.00 ▲ 9.06%
ATAI 4.57 ▲ 3.63%
GHRS 23.78 ▲ 6.26%
AXSM 233.72 ▲ 0.38%
NBIX 158.06 ▲ 1.07%
ACAD 21.82 ▲ 0.88%
LLY 1095.92 ▼ 2.74%
JNJ 226.73 ▼ 1.76%
ABBV 216.57 ▼ 0.94%
CURLF 3.56 ▲ 12.66%
GTBIF 8.01 ▲ 5.67%
TCNNF 9.67 ▲ 14.62%
VRNO 1.19 ▲ 6.25%
TLRY 5.59 ▼ 1.06%
CGC 1.11 ▼ 0.89%
MSOS 5.04 ▼ 1.56%
MJ 27.18 ▼ 0.18%
TDOC 7.94 ▲ 5.73%
HIMS 26.16 ▲ 3.07%
TALK 5.20 ▲ 0.19%
LFMD 4.37 ▼ 4.79%
ACHC 23.26 ▼ 2.10%
UHS 149.49 ▼ 0.42%
CMPS 13.00 ▲ 9.06%
ATAI 4.57 ▲ 3.63%
GHRS 23.78 ▲ 6.26%
AXSM 233.72 ▲ 0.38%
NBIX 158.06 ▲ 1.07%
ACAD 21.82 ▲ 0.88%
LLY 1095.92 ▼ 2.74%
JNJ 226.73 ▼ 1.76%
ABBV 216.57 ▼ 0.94%
CURLF 3.56 ▲ 12.66%
GTBIF 8.01 ▲ 5.67%
TCNNF 9.67 ▲ 14.62%
VRNO 1.19 ▲ 6.25%
TLRY 5.59 ▼ 1.06%
CGC 1.11 ▼ 0.89%
MSOS 5.04 ▼ 1.56%
MJ 27.18 ▼ 0.18%
TDOC 7.94 ▲ 5.73%
HIMS 26.16 ▲ 3.07%
TALK 5.20 ▲ 0.19%
LFMD 4.37 ▼ 4.79%
ACHC 23.26 ▼ 2.10%
UHS 149.49 ▼ 0.42%

Psychedelics

Psilocybin, MDMA, ibogaine, ketamine. Trials, regulation, religious exemptions, state programs.

First reporting in this vertical publishes this week.

In the pipeline

Program Sponsor Phase Status
MDMA-assisted therapy PTSD Lykos Therapeutics NDA Filed Resubmission planned after CRL
COMP360 psilocybin Treatment-resistant depression Compass Pathways Phase 3 Topline data expected
MM120 (LSD D-tartrate) Generalized anxiety disorder Mind Medicine Phase 3 Breakthrough designation
BPL-003 (intranasal mebufotenin) Treatment-resistant depression atai / Beckley Psytech Phase 2 Topline positive
CYB003 (deuterated psilocin) Major depressive disorder Cybin Phase 3 Breakthrough designation

Recent filings

CT
Psilocybin as a Novel Therapy for Residual Anhedonia
May 27, 2026 · psychedelics · research
SEC
Mind Medicine files 8-K
May 19, 2026 · mnmd
SEC
Mind Medicine files 8-K
May 12, 2026 · mnmd
SEC
atai Life Sciences files 8-K
May 7, 2026 · atai